Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10951 - 10975 of 11901 in total
PD-173952 is a potent Myt1 kinase inhibitor.
Investigational
Matched Description: … PD-173952 is a potent Myt1 kinase inhibitor.[A253067] …
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
Matched Description: … A version of [tabituximab barzuxetan] radiolabeled with yttrium-90. …
Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the...
Experimental
Illicit
Withdrawn
Matched Description: … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite ... It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers …
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational
Matched Description: … These cells have advantage over other MSCs because a large amount can be obtained from a single healthy ... CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from …
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing...
Investigational
Matched Description: … ., a privately held biopharmaceutical company. ... HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. …
7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative...
Investigational
Matched Description: … 7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan ... [DB00762], a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. …
OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of...
Investigational
Matched Description: … It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple …
Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors. It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high levels of intrinsic oxidative stress. In contrast, Bardoxolone in...
Investigational
Matched Description: … It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that …
Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine...
Experimental
Investigational
Matched Description: … Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. ... The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug …
BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.[L15002, L15007] BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728)...
Investigational
Matched Description: … BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a ... [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles …
OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter. It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical...
Investigational
Matched Description: … OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human ... Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter …
Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other...
Investigational
Matched Description: … Surotomycin has a fourfold greater in vitro potency than vancomycin against C. ... It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents ... effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a
Inhibitor of P38 Kinase is a solid. This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. This drug is known to target mitogen-activated protein kinase 14.
Experimental
Matched Description: … Inhibitor of P38 Kinase is a solid. This compound belongs to the indoles. ... These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to …
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … A chemically stable, cytidine analog that displays anti-tumor properties. ... It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as …
One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
Experimental
Matched Description: … One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae ... It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine …
IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.
Investigational
Matched Description: … IR208 is currently undergoing Phase II studies in a 200-patient trial. ... IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. …
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Investigational
Matched Description: … As a result, Sanofi stopped the development of the drug. ... Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X …
Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis.
Experimental
Matched Description: … Benzoctamine is a drug with two main uses. ... It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. …
MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD)...
Investigational
Matched Description: … MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin- ... Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. ... HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a
An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem]
Experimental
Matched Description: … An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine …
Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.
Experimental
Investigational
Matched Description: … A uracil nucleotide containing three phosphate groups esterified to the sugar moiety. …
Tiamulin is a pleuromutilin antibiotic drug that is used in veterinary medicine particularly for pigs and poultry.
Vet approved
Matched Description: … Tiamulin is a pleuromutilin antibiotic drug that is used in veterinary medicine particularly for pigs …
Lanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).
Investigational
Matched Description: … Lanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants …
SB-1578 is under investigation in clinical trial NCT01235871 (A Single and Multiple-Dose Study of SB1578).
Investigational
Matched Description: … SB-1578 is under investigation in clinical trial NCT01235871 (A Single and Multiple-Dose Study of SB1578 …
Displaying drugs 10951 - 10975 of 11901 in total